rss
Br J Ophthalmol 2008;92:1065-1068 doi:10.1136/bjo.2008.138560
  • Original Article
    • Clinical science

The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography

  1. M Hajali1,
  2. G A Fishman1,
  3. R J Anderson2
  1. 1
    Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA
  2. 2
    Department of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL, USA
  1. Dr G A Fishman, Department of Ophthalmology and Visual Sciences (MC 648), Room 3.85, Eye and Ear Infirmary, 1855 W Taylor Street, Chicago, IL 60612-7234, USA; gerafish{at}uic.edu
  • Accepted 25 April 2008

Abstract

Aims: To determine the prevalence of cystoid macular oedema (CMO) in retinitis pigmentosa (RP) patients of various genetic subtypes using optical coherence tomography (OCT).

Methods: We performed a complete ocular examination on 124 RP patients including best corrected visual acuity, intraocular pressure measurement, anterior segment and a detailed fundus exam. OCT images were then acquired using two different units. The presence of hypo-reflective lacunae was used to diagnose CMO.

Results: Of the 124 patients, 47 showed CMO in at least one eye (38%), while 34 showed CMO in both eyes (27%). The prevalence of CMO in at least one eye for autosomal dominant (AD) patients was 52%, for autosomal recessive (AR) 39%, isolated 39%, Usher II 35% and none in the X linked recessive (XL) group. Using a chi-square analysis, no statistical significant difference was found for the prevalence of “bilateral CMO” (p = 0.60) or “CMO in at least one eye” (p = 0.59) among the AD, AR, isolated and Usher II genetic subtypes.

Conclusion: Because of its notable prevalence, it would seem prudent to screen RP patients by OCT for the possible presence of CMO, to identify those amenable to treatment and also for future treatment trials when monitoring visual acuity.

Footnotes

  • Funding: Supported by funds from the Foundation Fighting Blindness, Owings Mills, Maryland; Grant Healthcare Foundation, Lake Forest, Illinois; NIH core grant EYOO1792; and an unrestricted departmental grant from Research to Prevent Blindness. The funding source had no involvement in the design of this study; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

  • Competing interests: None.

  • Ethics approval: This study was approved by an institutional review board and the University of Illinois ethics committee, and was performed in accordance with the tenets of the Declaration of Helsinki.

  • Patient consent: Obtained.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.